In The News Archivi

IRBM to collaborate with MSD to develop peptides against coronavirus

In The News, Press Releases

Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)
Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2.

IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford

In The News, Press Releases

Pomezia, Italy - Advent Srl, an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19.

In Memory of Maurizio Botta: His Vision of Medicinal Chemistry

In The News

IRBM’s medicinal chemists are incredibly proud to have contributed 3 articles to a special issue of the ACS Medicinal Chemistry Letters in memory of Professor Maurizio Botta. Many of our chemistry team were former students of the professor and are therefore thrilled to be part of this tribute.

IRBM supporting the effort to cope with the impact of coronavirus

In The News

There are many ways to face the impact of coronavirus. Due to the worldwide pandemic, there is a blood shortage in several hospitals. The staff at IRBM set up, in partnership with Ema-Roma, a Blood Donation Day. This highly worthwhile…

IRBM’s Chief Science Officer, Carlo Toniatti is featured in the Medicine Maker’s Power List

In The News, Scientific Contributions

Carlo joins other leading authorities in drug discovery and development as part of the Biopharmaceuticals category in the Medicine Maker Power List. In his interview he reviews future trends in drug development and some of the defining moments of his…

BBC came to film IRBM’s Advent GMP facility

In The News

Recently the BBC came to film IRBM’s Advent GMP facility and interview our Managing Director, Matteo Liguori about the manufacture of the Covid-19 vaccine...

Targeting The HIV-1 Nucleocapsid Protein To Fight Antiretroviral Drug Resistance

Dihydroxypyrimidine Scaffold to Target HIV‑1 Nucleocapsid Protein

In The News, Scientific Contributions

IRBM and their collaborators’ at the universities of Strasbourg and Siena have recently published a paper in the ACS Medicinal Chemistry Letters which describes their approach to the identification of a 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new…

The Medicine Maker. Onward in Oncology: Lessons Learned with Carlo Toniatti

In The News, Scientific Contributions

IRBM’s Chief Science Officer, Carlo Toniatti is once again featured in the Medicine Maker. This time he takes us on a journey from the clinic, to academia, to industry – where he spent over two decades developing anti-cancer drugs. Carlo…

IRBM unleashes its passion for science on the global drug discovery market

In The News

A conversation with Matteo Liguori, Managing Director of IRBM

IRBM publishes in Nature Scientific Reports on the Janus effect of glucocorticoids on the differentiation of muscle fibro/adipogenic progenitors

In The News

Fibro-adipogenic progenitors (FAPs) are known to cause muscle impairment in non-physiological settings, such as aging and myopathies, by promoting fibrosis and fat infiltration. IRBM and their collaborators at the University of Rome Tor Vergata, screened a library of 1,120 FDA/EMEA…